Advertisement

SAN DIEGO, Oct. 13 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported on new preclinical research findings that Excellagen, a topically applied formulated collagen wound management gel product candidate, activates platelet release of platelet-derived growth factor (PDGF) locally at the wound site.  This growth factor has been shown to play an essential role in the wound healing process.

(Logo:  http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

This research effort was undertaken for Cardium by an independent contract testing laboratory in an effort to further understand the statistically significant accelerated wound healing (as measured by the overall reduction in wound radius) in chronic diabetic foot ulcers that was observed in Cardium's Matrix clinical study during the first two weeks following administration of Excellagen formulated collagen (2.6%) topical gel, compared to the study's standard of care arm.   In addition, detailed reviews of previous preclinical studies, the Matrix clinical study protocol and Excellagen application practices were undertaken.

Based on data from this new research study and review, Cardium researchers now believe that the Excellagen product candidate activates the release of PDGF (and potentially other important growth factors) from platelets that migrate into the wound site with the influx of blood resulting from surgical wound debridement, a procedure that is commonly used by physicians and wound care specialists as a component of standardized wound care.  In the Matrix clinical study, Excellagen formulated collagen was applied immediately following debridemen

'/>"/>

SOURCE

Advertisement
Advertisement